JanOne jumps on progress towards Phase 2 trial

AI Financial

08/06/2021 15:42

** JanOne  JAN.O  shares up 5.87% at $7.64 after resuming trade
following volatility halt
    ** Company said it had completed the first batch production
of its JAN101 treatment for Peripheral Artery Disease ahead of
its upcoming Phase 2b trial  urn:newsml:reuters.com:*:nPn5YspqMa
    ** JAN shares had reached session high of $8.85
    ** With move on Tues, stock up ~11% for June after declines
in prior four months; up ~56% YTD
    ** The number of JAN shares out on loan for shorting as of
yesterday's close was 412,300, according to FIS Astec Analytics,
down by 17,600 in the prior session; the amount of shares on
loan as a percentage of shares outstanding stood at 20.3%
    ** FIS has a borrowing activity rating of 10 out of 10 on
JAN, indicating shares are expensive to borrow and scarce

 ((charles.mikolajczak@tr.com; @ChuckMik; Reuters Messaging:
charles.mikolajczak.thomsonreuters.com@reuters.net))